Results 111 to 120 of about 6,225,903 (287)

Insights Into the Antigenic Repertoire of Unclassified Synaptic Antibodies

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective We sought to characterize the sixth most common finding in our neuroimmunological laboratory practice (tissue assay‐observed unclassified neural antibodies [UNAs]), combining protein microarray and phage immunoprecipitation sequencing (PhIP‐Seq). Methods Patient specimens (258; 133 serums; 125 CSF) meeting UNA criteria were profiled;
Michael Gilligan   +22 more
wiley   +1 more source

Nota sobre la revista "Ars Medica" [PDF]

open access: yes, 2012
Sinopsi breu sobre el contingut de la revista «Ars Medica», editada a Barcelona entre els anys 1925 i 1936. Notícia dels seus fundadors, principalment els doctors Bartrina, Battestini, Carulla, Mas Oliver, Otero, Salarich, Trias de Bes i Vanrell. El 1932
Calbet i Camarasa, Josep M. (Josep Maria)
core  

Complementarity of Long‐Reads and Optical Mapping in Parkinson's Disease for Structural Variants

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Long‐read sequencing and optical genome mapping technologies have the ability to detect large and complex structural variants. This has led to the discovery of novel pathogenic variants in neurodegenerative movement disorders. Thus, we aimed to systematically compare the SV detection capabilities of OGM and ONT in Parkinson's disease.
André Fienemann   +17 more
wiley   +1 more source

Riesgo cardiovascular en estudiantes de la Universidad Tecnológica de Pereira, 2018 [PDF]

open access: yes, 2018
Este trabajo investigativo está inmerso dentro de un macroproyecto del Ministerio de Salud junto con las Secretarias Departamentales y las EPS, gracias al trabajo que se está realizando a nivel nacional, decidimos aportar a este proyecto realizando la ...
Alvarado Laurín, Luisa Fernanda   +1 more
core  

Development of a Personalized Visualization and Analysis Tool to Improve Clinical Care in Complex Multisystem Diseases With Application to Scleroderma

open access: yesArthritis Care &Research, EarlyView.
Objective In complex diseases, it is challenging to assess a patient's disease state, trajectory, treatment exposures, and risk of multiple outcomes simultaneously, efficiently, and at the point of care. Methods We developed an interactive patient‐level data visualization and analysis tool (VAT) that automates illustration of the trajectory of a ...
Ji Soo Kim   +18 more
wiley   +1 more source

Renal cell cancer among African Americans: an epidemiologic review

open access: yesBMC Cancer, 2011
Incidence rates for renal cell cancer, which accounts for 85% of kidney cancers, have been rising more rapidly among blacks than whites, almost entirely accounted for by an excess of localized disease.
Lipworth Loren   +2 more
doaj   +1 more source

Metabolic reprogramming in renal cancer: Events of a metabolic disease.

open access: yesBiochimica et biophysica acta. Reviews on cancer, 2021
S. Chakraborty   +4 more
semanticscholar   +1 more source

Reflexiones sobre la información en salud y su dimensión ética1 [PDF]

open access: yes, 2014
It is argued that, in health, the ethical problems that beset or occur in the handling of information reaching under a special dimension of meaning that this information is for the health of the population.
Silva Ayçaguer, Luis Carlos
core  

Serum Uric Acid Levels in Older Adults: Associations With Clinical Outcomes and Implications for Reference Intervals in Those Aged 70 Years and Over

open access: yesArthritis Care &Research, EarlyView.
Objective Reports have linked both high and low serum uric acid (SUA) levels to adverse health outcomes. This study aimed to establish a reference interval for SUA in older adults and assessed its association with clinically relevant outcomes in relatively healthy, community‐dwelling individuals aged ≥70 years old.
Amanda J. Rickard   +15 more
wiley   +1 more source

El efecto nefrotóxico del Sunitinib [PDF]

open access: yes, 2019
El sunitinib (Su) es un fármaco antineoplásico, dirigido al tratamiento en primera línea de pacientes con carcinoma de células renales metastásicas (CCRm).
Alba Gutiérrez, Manuela
core  

Home - About - Disclaimer - Privacy